Egevad L - Search Results

1

Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.

Hugosson J, Månsson M, Wallström J, Axcrona U, Carlsson SV, Egevad L, Geterud K, Khatami A, Kohestani K, Pihl CG, Socratous A, Stranne J, Godtman RA, Hellström M; GÖTEBORG-2 Trial Investigators. Hugosson J, et al. Among authors: egevad l. N Engl J Med. 2022 Dec 8;387(23):2126-2137. doi: 10.1056/NEJMoa2209454. N Engl J Med. 2022. PMID: 36477032 Free PMC article. Clinical Trial.

2

Relatively high risk of treatment failure after prostatectomy: tumour grade, histopathological stage and the preoperative serum PSA level are key prognosticators.

Andersson J, Ekman P, Egevad L, Hellström M. Andersson J, et al. Among authors: egevad l. Scand J Urol Nephrol. 2001 Dec;35(6):453-8. doi: 10.1080/003655901753367541. Scand J Urol Nephrol. 2001. PMID: 11848423

3

Prognostic value of the Gleason score in prostate cancer.

Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Egevad L, et al. BJU Int. 2002 Apr;89(6):538-42. doi: 10.1046/j.1464-410x.2002.02669.x. BJU Int. 2002. PMID: 11942960

4

Interobserver reproducibility of percent Gleason grade 4/5 in total prostatectomy specimens.

Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L. Glaessgen A, et al. Among authors: egevad l. J Urol. 2002 Nov;168(5):2006-10. doi: 10.1016/S0022-5347(05)64283-8. J Urol. 2002. PMID: 12394696

5

Interobserver reproducibility of percent Gleason grade 4/5 in prostate biopsies.

Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L. Glaessgen A, et al. Among authors: egevad l. J Urol. 2004 Feb;171(2 Pt 1):664-7. doi: 10.1097/01.ju.0000108198.98598.00. J Urol. 2004. PMID: 14713782

6

Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens.

Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L. Glaessgen A, et al. Among authors: egevad l. Virchows Arch. 2004 Jul;445(1):17-21. doi: 10.1007/s00428-004-1034-0. Epub 2004 May 20. Virchows Arch. 2004. PMID: 15156317

7

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P. Pavlenko M, et al. Among authors: egevad l. Br J Cancer. 2004 Aug 16;91(4):688-94. doi: 10.1038/sj.bjc.6602019. Br J Cancer. 2004. PMID: 15280930 Free PMC article. Clinical Trial.

8

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.

Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Roos AK, et al. Among authors: egevad l. Prostate. 2005 Feb 15;62(3):217-23. doi: 10.1002/pros.20135. Prostate. 2005. PMID: 15389792

9

Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.

Ozenci V, Miller AM, Palmborg A, Egevad L, Jaremko GA, Kälkner KM, Pisa P. Ozenci V, et al. Among authors: egevad l. Prostate. 2005 Sep 15;65(1):20-6. doi: 10.1002/pros.20229. Prostate. 2005. PMID: 15800933

10

Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment.

Josefsson A, Wikström P, Granfors T, Egevad L, Karlberg L, Stattin P, Bergh A. Josefsson A, et al. Among authors: egevad l. Eur Urol. 2005 Oct;48(4):577-83. doi: 10.1016/j.eururo.2005.05.016. Eur Urol. 2005. PMID: 15990221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

413 results

Search Page